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Abstract
Cellular chloride transport has a fundamental role in cell volume regulation and renal 
salt handling. Cellular chloride entry or exit are mediated at the plasma membrane by 
cotransporter proteins of the solute carrier 12 family. For example, NKCC2 resorbs 
chloride with sodium and potassium ions at the apical membrane of epithelial cells in 
the kidney, whereas KCC3 releases chloride with potassium ions at the basolateral 
membrane. Their ion transport activity is regulated by protein phosphorylation in 
response to signaling pathways. An additional regulatory mechanism concerns the 
amount of cotransporter molecules inserted into the plasma membrane. Here we 
describe that tyrosine phosphorylation of NKCC2 and KCC3 regulates their plasma 
membrane expression levels. We identified that spleen tyrosine kinase (SYK) 
phosphorylates a specific N-terminal tyrosine residue in each cotransporter. 
Experimental depletion of endogenous SYK or pharmacological inhibition of its kinase 
activity increased the abundance of NKCC2 at the plasma membrane of human 
embryonic kidney cells. In contrast, overexpression of a constitutively active SYK 
mutant decreased NKCC2 membrane abundance. Intriguingly, the same experimental 
approaches revealed the opposite effect on KCC3 abundance at the plasma 
membrane, compatible with the known antagonistic roles of NKCC and KCC 
cotransporters in cell volume regulation. Thus, we identified a novel pathway 
modulating the cell surface expression of NKCC2 and KCC3 and show that this same 
pathway has opposite functional outcomes for these two cotransporters. The findings 
have several biomedical implications considering the role of these cotransporters in 
regulating blood pressure and cell volume.
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Abbreviations
FBS- fetal bovine serum; KCC3- K-Cl cotransporter (KCC) isoform 3; NKCC2- Na-K-
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1. Introduction
Cellular chloride transport plays important roles in the maintenance of cell volume, the 
regulation of blood pressure, and in neuronal excitability (Kahle et al. 2006; Pedersen 
et al. 2013; Watanabe and Fukuda 2015). One important family of plasma membrane 
proteins that mediate chloride entry into or exit from cells are the cotransporters of the 
solute carrier 12 family. Their activity remains electroneutral because Cl- is 
cotransported with either Na+ and/or K+ ions and the driving force is the electrochemical 
gradient established by the ATP-dependent Na+/K+–ATPase. Two phylogenetic and 
functional subgroups exist in the SLC12 family: the genes SLC12A1 –A3 encode 
Na+/K+/Cl- cotransporters required for Cl- entry into cells, while the SLC12A4-A7 genes 
encode K+/Cl--cotransporters mediating Cl- exit (Arroyo et al. 2013). 
The SLCA1-A3 members are known as NKCC2, NKCC1 and NCC, respectively. 
NKCC2 is an apical cotransporter mostly expressed in the thick ascending limb of the 
loop of Henle (TAL) and the macula densa of the proximal nephron, and is a key 
mediator of renal Na+ and Cl- reabsorption (Gamba and Friedman 2009; Ares et al. 
2011). Its specific inhibition by diuretic drugs such as bumetanide or furosemide is 
used to treat high blood pressure. NKCC1 is ubiquitously expressed to assure cell 
volume regulation. Its basolateral Cl- entry activity is further important in sustaining 
apical Cl- secretion in certain epithelia. NCC is found in the apical membrane of Cl--
resorbing cells of the distal convoluted tubule of the nephron (McCormick et al. 2008; 
Moes et al. 2014). Mutations in the NKCC2 or NCC genes cause the rare genetic 
diseases Bartter (type I) or Gitelman syndromes characterized by low blood pressure 
and renal NaCl wasting (Kleta and Bockenhauer 2006; Esteva-Font et al. 2012).
On the other hand, the SLC12A4-A7 genes encode the K+/Cl- cotransporters KCC1-
KCC4, which move Cl- out of cells. KCC1 is ubiquitously expressed and important for 
general cell volume regulation. While KCC2 is neuron-specific, KCC3 and KCC4 are 
both expressed in neurons and the kidney, where KCC3 is specifically expressed in 
the proximal tubule. Inherited mutations in the KCC3 gene or its disruption in mouse 
models cause peripheral neuropathy (Howard et al. 2002; Kahle et al. 2016).
Of great importance for cellular homeostasis is the synchronized activity of both 
subgroups within the same cell. For example, during cell volume regulation, the cell 
shrinkage caused by osmotic stress is counteracted by activating Cl- entrance through 
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NKCC and simultaneously inhibiting Cl- exit via KCC activity. Also, epithelia that 
reabsorb or secrete Cl-, such as the kidney or lungs, respectively, require synchrony 
between apical and basolateral Cl- transport activities. This requires the existence of 
regulatory mechanisms that act simultaneously upon NKCC and KCC cotransporters, 
but with opposite functional outcome, and this has been particularly well-documented 
in neurons (Adragna et al. 2015; Zhang et al. 2016). 
One such mechanism that regulates the activity of SLC12 cotransporters in opposite 
ways involves their post-translational modification by protein kinases: while 
phosphorylation activates NKCC cotransporters (Vitari et al. 2006; Richardson et al. 
2011), it inhibits KCCs (Kahle et al. 2006, 2015). Responsible for this phosphorylation 
are the highly homologous kinases SPAK (Ste20/SPS1-related proline- and alanine-
rich kinase) and OSR1 (or oxidative stress-responsive kinase) (Piechotta et al. 2002). 
Both contain a conserved carboxyl (C)-terminal domain, which specifically recognizes 
an amino (N)-terminal RFxV/I motif in the peptide sequences of SLC12A members, for 
example R20FQV in NKCC2 and R14FMV in KCC3a. This interaction allows binding 
and subsequent phosphorylation of the cotransporters at distinct threonine (Thr) 
residues, for example, at Thr95, 100 and 105 in NKCC2, and at Thr991 and Thr1048 
in KCC3 (Rinehart et al. 2009; de los Heros et al. 2014). In cells, endogenous KCC3 
phosphorylation at Thr991 and Thr1048 is strongly reduced when cells are exposed to 
hypotonic conditions, and experimentally induced dephosphorylation at these sites 
activates ion transport by KCC3.
SPAK and OSR1, in turn, are activated by members of the WNK protein kinase 
subfamily (Veríssimo and Jordan 2001), which phosphorylate critical Thr residues 
within the T-loop motif of the catalytic domain, namely SPAK Thr233 or OSR1 Thr185 
(Vitari et al. 2005; Zagórska et al. 2007). WNK kinases were proposed to act as 
upstream sensors of intracellular Cl- levels since structural analysis revealed a Cl--
binding pocket around the activation loop motif DLG of the WNK catalytic domain (Piala 
et al. 2014; Terker et al. 2016). Other physiologic stimuli leading to activation of the 
WNK-SPAK/OSR1 pathway for renal chloride uptake regulation are hormones. 
Whereas angiotensin II stimulates NCC (Castaneda-Bueno et al. 2012), vasopressin 
stimulates NKCC2-mediated ion transport (Kim et al. 1999; Giménez and Forbush 
2003; Welker et al. 2008; Saritas et al. 2013).
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Besides cotransporter phosphorylation, another post-translational mechanism exists 
to rapidly regulate the cellular ion transport capacity: the amount of cotransporter 
protein present at the cell surface. Although membrane protein levels at the cell surface 
also depend on the delivery rate of newly synthesized protein, the effective balance 
between endocytosis and recycling of internalized transporter protein back to the cell 
surface can assume important regulatory roles, for example in insulin-stimulated 
glucose uptake (Leto and Saltiel 2012). When studied in the TAL, only around 5% of 
total NKCC2 protein was located at the apical membrane under basal conditions (Ares 
et al. 2011). In the kidney, vasopressin stimulates salt retention through NKCC2 at 
various levels, including protein trafficking to the cell surface (Ares et al. 2011; Castrop 
and Schießl 2014). These effects are mediated by the second messenger cyclic AMP 
(cAMP) and NKCC2 surface levels also increased after exposing isolated TAL tubules 
to cAMP (Giménez and Forbush 2003; Ortiz 2006)). The latter involves NKCC2 
phosphorylation by protein kinase A (PKA) at Ser130 and Ser879 (Gunaratne et al. 
2010) and experiments using the PKA inhibitor H-89 showed a decrease in the 
abundance of apical NKCC2 (Caceres et al. 2009). The cAMP-stimulated NKCC2 
surface delivery in TALs was proposed to occur from intracellular storage vesicles 
(Giménez and Forbush 2003; Ortiz 2006) and be mediated by the vesicle-associated 
membrane protein 2 (VAMP2) (Caceres et al. 2014); however, the molecular 
mechanisms regulating the cell surface abundance are poorly understood. In the case 
of KCC3, about 60% of total KCC3 was detected at the plasma membrane of HEK293 
cells under isotonic conditions, with the majority of this fraction being phosphorylated 
at Thr991 and Thr1048 and thus inactive (Rinehart et al. 2009).
A novel mechanism to modulate ion transport was recently described for the Cl- 
channel cystic fibrosis transmembrane conductance regulator (CFTR), which when 
mutated leads to a deregulated epithelial fluid transport, namely in the lung, causing 
the genetic disease cystic fibrosis. Spleen tyrosine kinase (SYK) was found to regulate 
CFTR surface abundance through phosphorylation of Tyr512 in the nucleotide-binding 
domain 1 (NBD1) of CFTR (Mendes et al. 2011). In human airway epithelial cells, 
downregulation of endogenous SYK or overexpression of catalytically active SYK 
confirmed its regulatory role. Here, we describe that protein kinase SYK also 
phosphorylates the cotransporters NKCC2 and KCC3 within their N-terminal 
cytoplasmic domains. This resulted in the modulation of their cell surface abundance, 
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however, with opposite functional consequences: phosphorylation decreased NKCC2 
but increased KCC3 levels at the cell surface. 
2. Materials and Methods
2.1. Cell culture and transfections
MMDD1 (mouse macula densa-derived-1) cells (gift from K. Mutig, Charité, Berlin), 
and HEK293 (human embryonic kidney) cells were maintained in Dulbecco’s minimal 
essential medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS) 
(Invitrogen). Human kidney 2 cells (HK-2) were a gift from M.J. Valente, REQUIMTE, 
Portugal and maintained in Dulbecco’s modified eagle medium/nutrient mixture F-12 
(DMEM/F12) supplemented with 10% FBS. All cells were regularly checked for 
absence of mycoplasm infection. For cell polarization, MMDD1 cells were grown on 
transwell, collagen IV-coated porous (0.4 m) PET filter inserts (6-well size with 24.5 
mm diameter, from Corning) in medium supplemented with 2.5% FBS for 10-15 days, 
until they reached a transepithelial electrical resistance (TEER) of 600, as measured 
with a Chopstick Electrode (STX2 from WPI®) (Matos et al. 2018). 
For ectopic expression of complementary DNA-encoding plasmids, HEK293 cells were 
transfected at 80-90% confluence using Metafectene (Biontex, Germany) according to 
the manufacturer’s instructions. Transfection efficiencies were found to be around 
90%, as determined microscopically using a GFP-encoding expression vector. The 
amount of transfected plasmid DNA was kept constant at 8 g per 60 mm-dish, or 4 
g per 35 mm-dish, and adjusted with empty vector if required. Cells were analyzed 
after 20 h for biochemical assays.
For downregulation of endogenous proteins, 200 pmol of the corresponding small 
interfering RNAs (siRNAs) were transfected into HEK293 cells at 70% confluence 
using LipofectAMINE 2000 (Invitrogen) and cells were analyzed 48 h after transfection. 
siRNAs used were sc-29501 (Santa Cruz Biotechnology) against SYK and the control 
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
7
luciferase GL2 siRNA (siLUC) (5’-CGU ACG CGG AAU ACU UCG ATT) (Eurofins 
Genomics, Germany). 
For drug treatments, cells were incubated for 1 h with the vehicle DMSO (Sigma 
Aldrich) or with one of two different SYK inhibitors: BAY 61-3606 (2-(7-(3,4-
dimethoxyphenyl)-imidazol[1,2-c]pyrimidin-5-ylamino) nicotinamide) (Calbiochem) or 
PRT062607 (P505-15,BIIB057) (Selleckchem) at a final concentration of 8 nM, 7 nM 
and 1 nM, respectively. The stock solutions were prepared at least 1000-fold in DMSO.
For challenging cell volume regulation, HEK293 were co-transfected and drug-treated 
as above. Cells were transferred to pre-warmed isotonic medium (10 mM HEPES, pH 
7.5, 135 mM NaCl, 2 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 1 mM KH2PO4, 10 mM 
glucose, 20 mM mannitol), imaged at marked positions under a phase contrast 
microscope equipped with a digital camera, then washed and incubated for 10 min in 
pre-warmed hypertonic medium (isotonic medium containing 220 mM mannitol) before 
imaging the same microscopic fields again. Digital images were analyzed using the 
Image J software to calculate the area covered by individual cells, as an estimate for 
changes in cell dimension due to shrinkage. For each data point, at least 50 cells were 
measured in three independent microscopic fields from three independent assays.
2.2. DNA plasmids and constructs
NKCC2 cotransporter was amplified by polymerase chain reaction (PCR) from mouse 
cDNA clone 4236020 (IRAVp968F0329D) (Source Bioscience, UK) with primers Eco 
RI-F (5’ GAA TTC TCG GTC AGC ATC CCT TCC) and XhoI-R (5’ CTC TTA AAG CCT 
GAA GGA TGC TCG AG), cloned into pCR2.2 TOPO-TA vector, and then subcloned 
into the Eco RI and Xho I-sites of pcDNA3-Myc vector. KCC3 cotransporter was 
amplified from human cDNA clone 4826538 (Source Bioscience) by PCR with primers 
Eco RI-F (5’ ATG AGT GAG ATG T CT GGG G) and XhoI-R (5’ GTG ATC ACC ATT 
TAT TCA TAA), cloned into pCR2.2 TOPO-TA vector, and then subcloned as an Eco 
RI/ Not I fragment into pcDNA3-Myc vector. NKCC2-Nterm (nucleotides 33-486) was 
amplified from pcDNA3-Myc-NKCC2 with primers NKCC2-F (5’ GAT TCA GTG CCC 
AGT AAT ACC AAT CG) and NKCC2-R (5’ ACG GTG ATG GGA TAC C TG GAG ATG 
AA); KCC3-Nterm (nucleotides 4-405) was amplified from pcDNA3-Myc-KCC3 with the 
primers KCC3-F(5’ AGT GAG ATG TCT GGG GCC ACC A) and KCC3-R (5’ ACC TTC 
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ATG GGT GTC TAC CTC CCA). The two fragments were subcloned into the T7/His-
tagged pET28 vector (Merck4Biosciences). Subsequently, pET28-NKCC2 and pET28-
KCC3 were mutated at codon 45 and 63, respectively, from TAT to TTT to obtain 
pET28-NKCC2-Y45F and pET28-KCC3-Y63F, using the Quickchange mutagenesis kit 
(Stratagene, USA). 
Previously published constructs used in this study were YFP-SYK (SYK-wt), kinase-
dead YFP-SYK-K402R (SYK-kd) and pET-sumo-NBD1 (Mendes et al. 2011). All 
constructs were verified by automated DNA sequencing. The phosphomimetic and 
constitutively active SYK-Y352D construct was a gift from Dimitar G. Efremov (ICGEB, 
Rome, Italy) and provided in pcDNA3-Flag (Carsetti et al. 2009). 
2.3. Immunoprecipitation and Western blot procedures
For immunoprecipitation experiments, cells were grown in 60 mm dishes, transfected 
as described above and lysed on ice in 250 μL lysis buffer (50 mM Tris-HCl pH 7.5, 
1% NP-40, 150 mM NaCl, 10% glycerol, 0,1% (m/v) sodium dodecyl sulfate (SDS), 10 
mM MgCl2) supplemented with a protease inhibitor cocktail composed of 1 mM PMSF, 
1 mM 1,10-phenanthroline, 1 mM EGTA, 10 μM E64, and 10 μg/mL of each aprotinin, 
leupeptin, and pepstatin A (all from Sigma-Aldrich, Spain). The cell lysates were 
incubated for 2 h at 4ºC with the specified antibodies (1.5 μg/mL anti-GFP ab1218 
(Abcam) or 3 μg/mL anti-Myc clone 9E10 (M5546, Sigma-Aldrich)), then further 
incubated for 1 h with protein G-agarose beads (Roche), and finally washed three times 
in cold lysis buffer containing 200 mM NaCl. Proteins were solubilized from the beads 
in 2x SDS CFTR sample buffer (62.5 mM Tris-HCl pH 6.8, 3% SDS, 10% glycerol, 
0.02% bromophenol blue, 196.4 mM dithiothreitol (DTT) and separated in 10% SDS 
polyacrylamide gels in Protean III mini-gels (BioRad). Gels to assess NKCC2 and 
KCC3 expression contained 1% glycerol and were run at 4ºC (Mendes et al. 2011). 
Following electrophoresis, the separated proteins were transferred onto a PVDF 
membrane (BioRad) in a cooled Mini Trans-Blot cell (BioRad) at 300 mA, followed by 
Coomassie Brilliant Blue-staining to check for equal transfer. Membranes were blocked 
in TBS, 0.1% Triton X-100, 5% milk powder, probed using the indicated antibodies, 
and then incubated with a secondary peroxidase-conjugated antibody (BioRad) 
followed by chemiluminescence detection. Primary antibodies used for Western blots 
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were mouse anti-GFP (11814560001) from Roche, mouse anti-GFP (ab1218), rabbit 
anti-SYK (ab40781) and rabbit anti-SLC12A6 (ab92951) from Abcam, mouse anti-His 
(37-2900) from Invitrogen, mouse anti-Flag clone M2 (F3165) and anti-Myc clone 9E10 
(M5546) from Sigma-Aldrich, mouse anti-PCNA clone PC10 (NA03) from Calbiochem, 
and rabbit anti-NKCC2 from Millipore. 
2.4 Production of recombinant NKCC2, KCC3 and Sumo-NBD1 and in vitro 
protein kinase assays
For the production of recombinant protein fragments NKCC212-162, KCC32-135 , or 
CFTR-NBD1, the plasmids pET-NKCC2, pET-NKCC2-Y45F, pET-KCC3, pET-KCC3-
Y63F and pET-Sumo-NBD1 (Mendes et al. 2011) were expressed in the E. coli BL21 
strain upon induction with 0.75 mM isopropylthiogalactosidade (IPTG) and the bacterial 
pellets harvested at 1400 x g, for 30 min and frozen. For protein extraction, pellets 
were resuspended in either conventional lysis buffer (50 mM Tris-HCl pH 7.5, 50 mM 
NaCl, 5 mM MgCl2, 1 mM DTT) for NKCC2, NKCC2-Y45F, KCC3 and KCC3-Y63F, or 
lysis buffer containing 0.2% (v/v) Tween 20 in case of CFTR-NBD1, in the presence of 
the protease inhibitor cocktail described above, and then sonicated on ice in 6 cycles 
of 30 seconds with 10 seconds intervals (Sonics Vibra Cell sonicator, set at 40% 
power). Following centrifugation of the extracts at 1600x g, the supernatant was 
incubated with Ni-NTA agarose beads (Qiagen, Germany) for 1 h at 4ºC. Beads were 
washed twice with cold lysis buffer containing 20 mM imidazole and protease inhibitors. 
Recombinant proteins were eluted and stored in cold lysis buffer containing 250 mM 
imidazole. Proteins were quantified using the Precision Red Protein Assay Reagent 
(GL50 from Cytoskeleton) and stored in aliquots at -80ºC.
For in vitro protein kinase assay, cells were first lysed under stringent conditions in 250 
l lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 1% 
NP-40, 0.1% SDS) supplemented with protease inhibitors (see above). Following 
immunoprecipitation of SYK as described above, the resulting beads were washed 
three times in cold lysis buffer containing 300 mM NaCl, then resuspended in 20 l 
kinase reaction buffer (50 mM Tris-HCl pH 7.5, 10% glycerol, 1 mM DTT, 1 mM 
Na3VO4, 10 mM MgCl2, 100 M ATP) and incubated at 30ºC for 30 min, in order to 
reduce background autophosphorylation. Beads containing immunoprecipitated SYK-
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wt or SYK-kd were then incubated alone or with the corresponding substrate (200 ng 
of each recombinant protein) in the presence of 5 Ci -[32P] ATP at 30ºC for 30 min. 
Finally, 2x SDS sample buffer was added, samples boiled and separated by SDS-
polyacrylamide gel electrophoresis (PAGE) followed by protein transfer to PVDF 
membranes and Western blot. Membranes were exposed to X-ray films for 10 min to 
72 h and subsequently incubated with the respective antibodies in order to document 
protein quantities.
2.5 Biotinylation of cell surface proteins
HEK293 cells (either transfected or drug-treated as described above) were washed 
three times with warm culture medium to remove dead cells, and then placed on ice in 
a cold room. Cells were washed three times with ice-cold phosphate-buffered saline-
CM (PBS-CM) (PBS pH 8.0 containing 0.1mM CaCl2 and 1 mM MgCl2) to ensure arrest 
of endocytic traffic. Then, cells were incubated for 45 min with 0.5 mg/ml EZ-Link Sulfo-
NHS-SS-Biotin (sc-212981, from Santa Cruz Biotechnology) in PBS-CM to label all cell 
surface proteins. Cells were rinsed twice and incubated for 15 min on ice in ice-cold 
Tris/Glycine (100 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM MgCl2, 0.1 mM CaCl2, 10 
mM glycine, 1% BSA) to quench the biotinylation reagent. Cells were again washed 
three times with cold PBS-CM and lysed in 250 l pull-down buffer (50 mM Tris-HCl 
pH 7.5, 100 mM NaCl, 10% glycerol, 1% NP-40) in the presence of the protease 
inhibitor cocktail (described above). The cell lysates were harvested at 16000 x g at 
4ºC for 5 min. An aliquot of 40 l representing the total protein level was removed and 
added to 2x SDS CFTR sample buffer (see above), while 200 l lysate were added to 
45 l streptavidin-agarose beads (Sigma-Aldrich), previously incubated for 1 h in 1 ml 
cold pull-down buffer containing 2% non-fat milk powder, and washed three times in 
pull-down buffer. Lysates were incubated with the prepared beads for 1 h at 4ºC, the 
beads collected by centrifugation of 1 min at 6000 x g, and washed four times in cold 
wash buffer (100 mM Tris-HCl pH 7.5, 300 mM NaCl, 1% Triton X-100). Captured 
proteins were recovered in 20 l of 2x SDS CFTR sample buffer with 100 mM DTT and 
analyzed by Western blot with specific antibodies, as described above.
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2.6 Statistical analysis 
Data were analyzed using Student’s t-tests for paired samples or ANOVA tests 
followed by post-hoc Tukey’s tests when comparing multiple treatments. P<0.05 was 
accepted as the level of statistical significance. Shown data reflect the mean  SEM 
from at least three independent experiments.
3. Results
3.1. NKCC2 and KCC3 are a substrate for SYK protein kinase
Recently we described that spleen tyrosine kinase (SYK) can phosphorylate the 
CFTR chloride channel (Mendes et al. 2011). In particular, we found that the -Y512-D-
E-Y motif in the CFTR NBD1 domain was phosphorylated by SYK in vitro and that 
overexpression of SYK in cells inhibited the amount of CFTR present at the cell 
surface, without affecting total CFTR protein levels. 
Because SYK recognizes a well-defined peptide motif, in which the 
phosphorylated tyrosine is followed by two acidic amino acid residues (Y-E/D-E/D-X), 
we analyzed the protein sequence of 20 human ion channels or cotransporters 
involved in sodium, potassium or chloride transport for the presence of this SYK 
recognition motif (see Table 1). Only two further protein sequences were found to 
contain the motif: the Na+/K+/2Cl-cotransporter NKCC2 (SLC12A1) at tyrosine 45 and 
the K+/Cl-cotransporter KCC3 (SLC12A6) at tyrosine 63. Both NKCC2 and KCC3 
belong to the solute carrier family 12 (SLC12) of cation-chloride cotransporters and the 
predicted phosphorylation sites are located in their N-terminal cytoplasmic domains. 
We first tested whether SYK could phosphorylate NKCC2 and KCC3 in vitro. 
For this purpose, the N-terminal domains of both cotransporters (NKCC212-162; KCC32-
135) were cloned, expressed as recombinant proteins in E. coli and purified (Fig. 1A). 
As a negative control, fragments containing a mutated phosphorylation site were also 
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expressed, namely NKCC2-Y45 and KCC3-Y63F, in which the predicted target 
tyrosine was point-mutated to phenylalanine. In parallel, expression vectors encoding 
wild-type (wt) SYK, its kinase-dead (kd) mutant, or the corresponding empty vector 
were transfected into HEK293 cells and immunoprecipitated from cells lysed in RIPA 
buffer in order to minimize the contamination with other co-precipitating kinases from 
the cell lysate. The SYK-containing beads were washed in protein kinase buffer and 
then the recombinant substrate proteins (NBD1, NKCC2, NKCC2-Y45F, KCC3, KCC3-
Y63F) were added and incubated in the presence of radioactive ATP. As shown in Fig. 
1B, we observed that SYK-wt autophosphorylated whereas SYK-kd showed no such 
activity. Moreover, SYK-wt but not kinase-dead SYK clearly phosphorylated wt NKCC2 
and KCC3, confirming the absence of contaminant kinase activities. The NKCC2-Y45F 
and KCC3-Y63F mutants were poor substrates for SYK-wt. 
3.2. SYK activity decreases the expression of NKCC2 at the cell surface
Since SYK phosphorylated NKCC2 in vitro, we asked whether SYK would also 
modulate the expression of NKCC2 at the cell surface, as previously described for 
CFTR. Thus, HEK293 cells were co-transfected with Myc-tagged NKCC2 and one of 
the following expression vectors: empty vector, kinase-dead SYK (SYK-kd), or the 
constitutively active mutant SYK-Y352D (Carsetti et al. 2009). Kinase-dead mutants 
are commonly employed as dominant negative pathway inhibitors because they can 
interact with the substrate protein without phosphorylating it, thus blocking the access 
of the corresponding endogenous kinase. After 24 h the abundance of NKCC2 at the 
plasma membrane was analyzed by biotinylation of cell surface proteins. As shown in 
Fig. 2A, the expression of SYK-kd increased over 2-fold the amount of NKCC2 at the 
cell surface, whereas expression of constitutively active SYK led to a near 2-fold 
decrease.
Next we tested the effect of downregulating endogenous SYK in HEK293 cells. 
Cells were transfected with SYK-specific siRNAs (sc-29501 from Santa Cruz 
Biotechnology), which were able to downregulate SYK expression to approximately 
15% of its normal levels (Fig. 2B, grey bars). Under these conditions, we observed a 
near 6-fold increase for NKCC2 at the cell surface, suggesting again that SYK-
mediated phosphorylation of NKCC2 mediates its internalization (Fig. 2B, black bars). 
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Finally, we used pharmacological inhibitors of SYK kinase activity. HEK293 cells 
were treated with one of two different SYK inhibitors (BAY 61-3606 and PRT062607) 
or with the control solvent DMSO for 1 h. Subsequent, analysis of biotinylated surface 
proteins showed that these inhibitors increased the amount of NKCC2 at the cell 
surface by 2.5 and 3.5-fold, respectively (Fig. 2C). 
In order to demonstrate the effect of SYK inhibition in physiologically more 
relevant cells, we cultured the mouse macula densa-derived cell line (MMDD1). 
Although we found that these cells clearly expressed endogenous NKCC2 and SYK 
by Western blot analysis, the biotinylation assay was not able to detect NKCC2 at the 
surface, even when cells were grown on membrane filters and had formed a polarized 
cell monolayer (see Suppl. Fig. S1).
3.3. SYK activity increases the expression of KCC3 at the cell surface
In order to compare how SYK activity would modulate the expression of KCC3 
at the cell surface, HEK293 cells were co-transfected with Myc-tagged KCC3 and the 
above-described YFP-tagged expression vectors. When the abundance of KCC3 at 
the plasma membrane was analyzed by biotinylation of cell surface proteins, the 
expression of constitutively active SYK was found to upregulate by 2-fold the 
abundance of KCC3 at the cell surface whereas expression of the SYK-kd protein 
produced the opposite result (Fig. 3A). Thus, SYK expression appeared to affect KCC3 
and NKCC2 in opposite ways. 
This effect was further confirmed, as described above for NKCC2, following 
downregulation of endogenous SYK in HEK293 cells (Fig. 3B) or following cell 
incubation with pharmacological inhibitors of SYK activity (Fig. 3C). In both cases, a 
decrease in the KCC3 levels at the cell surface was observed, confirming that SYK 
exerts opposite effects on NKCC2 and KCC3. A physiologically more relevant cell type 
is the human proximal tubule-derived cell line (HK-2), however, despite expressing 
endogenous KCC3 and SYK in total cell lysates, we were not able to detect KCC3 
expression at the cell surface (see Suppl. Fig. S1).
3.4 SYK activity modulates the cell surface expression of NKCC2 and KCC3 in 
opposite ways in the same cell.
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As described in the Introduction, previous data indicated that a concerted regulation of 
NKCC and KCC within the same cell is important for cell volume regulation. In case of 
NKCC1 and KCC3 it has been well-known that both cotransporters are expressed in 
the same cell. In order to provide proof-of-principle that the SYK-mediated tyrosine 
phosphorylation of NKCC2 and KCC3 could convey a concerted regulation within the 
same cell, we co-transfected HEK293 cells with Myc-NKCC2 and Myc-KCC3, then 
treated them with SYK inhibitors before determining the amount of biotinylated cell 
surface levels of both cotransporters. In this experiment, we discriminated between 
NKCC2 and KCC3 by using antibodies specific for each cotransporter, instead of the 
anti-Myc antibody. The results are shown in Fig 4A and revealed that two different SYK 
inhibitors (BAY 61-3606 or PRT062607) were able to increase NKCC2 levels at the 
cell surface roughly two-fold, while simultaneously decreasing KCC3 levels in the same 
cell.
3.5 SYK activity contributes to cell-volume regulation.
In order to determine whether the effect of SYK inhibition on cell surface expression 
(more NKCC2 and less KCC3) would confer a functional advantage to the cell, we 
challenged co-transfected HEK293 cells by incubating them for 10 min in hypertonic 
medium. Under these osmotic conditions, cells are known to stimulate NKCC activity 
to increase ion uptake and compensate the osmotic difference. To investigate these 
effects, we used a simple semi-quantitative microscopy approach to estimate 
variations in cell dimension. Phase contrast microscopic images were taken 10 min 
after exposure to hypertonic medium and the area occupied by individual cells 
measured using NIH ImageJ software. These analyses revealed that after incubation 
in hypertonic medium, control cells occupied an area 40% smaller than in isotonic 
medium, indicating a cell body retraction due to shrinkage (Fig. 4B). In contrast, when 
co-transfected cells were pre-treated with the SYK inhibitor BAY 61-3606 (i.e. 
increasing the amount of NKCC2 at the cell surface), they occupied 93% of the area 
compared to isotonic medium, indicating a more efficient compensation of cell volume 
(Fig. 4B).
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4. Discussion
The results presented in this work identify for the first time that phosphorylation on 
tyrosine residues modulates the cell surface levels of two key ion cotransporters, 
NKCC2 and KCC3, involved in regulating electrolyte balance and cell volume. 
Besides identifying their phosphorylation sites by protein kinase SYK in vitro, we 
provide evidence that co-expression of a constitutively active SYK into human cells 
decreased NKCC2 but increased KCC3 cell surface expression, and that the opposite 
effects were observed upon depletion of endogenous SYK or pharmacological 
inhibition of its kinase activity. Another major novelty reported here is that the same 
mechanism can apparently be used by cells to regulate NKCC2 and KCC3 in opposite 
ways.
The topology of both NKCC2 and KCC3 features a central hydrophobic region with 12 
transmembrane spanning domain that is flanked by two cytoplasmic domains: a 180-
amino acid N-terminal and a longer 470-amino acid C-terminal domain (Ares et al. 
2011). The N-terminal domain of NKCC2 is particularly well studied and harbors 
important regulatory functions: it includes the SPAK/OSR1 recognition motif R20FQV 
and contains the ion transport-regulating phosphorylation sites Thr95, 100 and 105 
(Rinehart et al. 2009; de los Heros et al. 2014). In this work, we identified another 
regulatory site in this domain, the SYK-phosphorylated Tyr45 residue. 
The SYK-phosphorylatable tyrosine 45 belongs to the first coding exon and locates to 
the N-terminal cytosolic domain and is thus present in all known NKCC2 splicing 
variants. The functional properties of NKCC2 are modulated by the generation of at 
least six alternative splicing variants (Simon et al. 1996; Mount et al. 1999). Three 
variants derive from inclusion of the mutually exclusive cassette exons 4A, 4B or 4F, 
which all encode part of transmembrane 2 (TM2) with the adjacent intracellular loop 
and confer different ion transport kinetics (Castrop and Schnermann 2008). In addition, 
the terminal NKCC2 exon can give rise to two variants of different length depending 
on the use of two alternative polyadenylation sites. 
Similarly, the KCC3-encoding gene can generate two major splicing variants by 
inclusion of one of two alternative exons 1: KCC3a encodes 1141 amino acids and 
contains 59 additional N-terminal residues compared to KCC3b (Mercado et al. 2005); 
however, both retain the SYK-phosphorylatable tyrosine residue (i.e. Y122 in KCC3a 
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and Y63 in KCC3b). In case of KCC3, the crucial ion transport-regulatory sites that are 
phosphorylated by the WNK/SPAK/OSR1 pathway are located in the C-terminal 
domain. These sites are Thr991 and Thr1048 in KCC3a and are normally 
phosphorylated in isotonic conditions to inhibit ion transport activity. Curiously, all 4 
KCC members share highly homologous sites that are phosphorylated by 
SPAK/OSR1; however, a tyrosine motif for SYK phosphorylation was only identified in 
KCC3, indicating a specific control mechanism for this family member. Furthermore, 
the N-terminal domain of KCC3 contains Ser96 (Ser37 in KCC3b), which is also 
phosphorylated by SPAK to inhibit ion transport activity (Melo et al. 2013).
Recently, a WNK3-SPAK pathway was proposed to operate on NKCC1 and KCC3 in 
neuronal cells as the Cl−/volume-sensitive sensor that prevents cell swelling in 
response to osmotic stress. For this, a WNK3-dependent activation of SPAK triggers 
the simultaneous phosphorylation of NKCC1 at Thr203/Thr207/Thr212 and of KCC3 
at Thr991 and Thr1048 and this results in stimulation of NKCC1-mediated Cl− uptake 
and inhibition of KCC3-mediated Cl− extrusion (Adragna et al. 2015; Zhang et al. 2016). 
The importance for cell volume regulation of NKCC and KCC within the same cell had 
also been shown in pioneering studies using red blood cells (Lytle and McManus 
2002). 
The phosphorylation by SYK that is described in this manuscript could represent a 
similar concerted mechanism to regulate simultaneously NKCC2 and KCC3. Indeed, 
we provided proof-of-principle that such simultaneous regulation occurs when 
transfected NKCC2 and KCC3 are co-expressed in the same cell (Fig. 4). In addition, 
SYK inhibition increased the cells’ capability to compensate volume changes when 
exposed to hypertonic conditions. However, it remains to be establish whether cell 
types exist with simultaneous expression of NKCC2 and KCC3. In the kidney, 
expression of both cotransporters was assigned to different section of the nephron: 
NKCC2 in the TAL and KCC3 in the proximal tubule. More recently, however, NKCC2 
expression has been reported in colon (Zhu et al. 2011; Xue 2014; Xue and Tang 2016) 
and brain (Konopacka et al. 2015), tissues that also express KCC3.
With regard to NKCC2, its constitutive targeting to the apical membrane of renal MDCK 
cells was described to be mediated by a region encompassing amino acids 930 to 
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
17
1007 in the C-terminal cytosolic domain (Carmosino et al. 2008). Nevertheless, in the 
TAL only around 5% of total NKCC2 protein were found located in the apical membrane 
(Ares et al. 2011). Most likely, the maintenance of an intracellular NKCC2 pool 
represents a mechanism to rapidly increase the cellular ion transport capacity following 
appropriate stimuli (Mutig 2017), as known in the case of the glucose transporter 
GLUT4 in response to insulin (Leney and Tavaré 2009). Indeed, upon cAMP 
stimulation of TAL, cell surface NKCC2 increased rapidly, compatible with release from 
intracellular storage vesicles (Giménez and Forbush 2003; Ortiz 2006). 
Mechanistically, the vesicle-associated membrane protein 2 (VAMP2) was found to be 
involved (Caceres et al. 2014). Concerning KCC3, no such data are available.
Although the experiments described above revealed SYK phosphorylation of NKCC2 
or KCC3 as an additional mechanism that can regulate their traffic in HEK293 cells, it 
was not possible to validate the effect in the available physiologically relevant cell lines 
from the TAL or proximal tubule. Nevertheless, our findings have several potential 
biomedical implications. First, NKCC2 in the kidney represents the major target for 
diuretic drugs, the so-called loop diuretics such as furosemide, which are widely used 
in the treatment of hypertension. By decreasing the amount of sodium retained in the 
TAL, the plasma volume is reduced and helps to counteract high blood pressure. In 
this sense, modulating the SYK-mediated tyrosine phosphorylation of NKKC2 may 
represent an alternative pharmacologic target to treat hypertension, which does not 
rely on the inhibition of the ion transport activity but rather on the amount of NKCC2 
present at the cell surface. Although the protein kinase activity of SYK itself is a 
potential candidate, the widespread role of SYK signaling in immune cells (Mócsai et 
al. 2010) may lead to undesirable side effects. It will be interesting to determine what 
other cellular proteins are involved downstream of the phosphorylation event so that 
more specific drug targets can be identified. 
Second, the sequence context around the phosphorylated NKCC2 Tyr 63 could be 
involved in the variation of blood pressure found in the normal population, given that 
SLC12A1 was identified as a modifier gene during the genetic analysis of samples 
from the Framingham Heart Study, a defined population study over 35 years. Some 
genetic variants are protective against hypertension (Ji et al. 2008; Acuña et al. 2011; 
Welling 2014) because they decrease renal ion resorption. This may be caused by 
variants affecting NKCC2 biosynthesis, membrane trafficking, ion transport, or 
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
18
regulation, possibly including the tyrosine phosphorylation described in this 
manuscript.
Third, KCC3-mediated cell volume regulation is important for the normal development 
and functioning of peripheral nerves (Byun and Delpire 2007). In KCC3-/- mice, 
periaxonal swelling as a sign of a blocked efflux pathway was reported and followed 
by neurodegeneration. In humans, the corresponding autosomal recessive agenesis 
of the corpus callosum with peripheral neuropathy (ACCPN), also known as 
Andermann syndrome, is caused by truncating mutations in the KCC3-encoding 
SCL12A6 gene, or by missense mutations leading to defective regulation of its ion 
transport activity (Kahle et al. 2016). Although the WNK/SPAK-mediated 
phosphorylation of KCC3 at Thr1098 seems to be the major mechanism in the cellular 
response to acute cell volume changes, the contribution of the amount of KCC3 
present at the cell surface remains to be clarified. Myelin and axonal disorders have a 
wide spectrum of underlying etiologies but are common to a large group of human 
neurological diseases (Byun and Delpire 2007) and may benefit from knowledge on 
KCC3 regulation.
Finally, various ion channels and cotransporters promote crucial cellular functions 
during tumor progression, based on their roles in cell volume regulation, membrane 
potential and interaction at the cell surface with receptors or other membrane proteins 
(Kunzelmann 2005; Schönherr 2005). Accordingly, changes in expression or 
regulation of KCC3 have been observed in primary tumors, such as from brain, cervix, 
breast, ovary or esophagus (Shen et al. 2004; Hsu et al. 2007b, a; Gagnon 2012; 
Kitagawa et al. 2013; Shiozaki et al. 2014; Chiu et al. 2014). Any upregulation of K+/Cl- 
cotransport activity was found to benefit cancer cells in their growth or invasiveness 
related to epithelial mesenchymal transition (Shen et al. 2001; Chen et al. 2010; Salin-
Cantegrel et al. 2013). Thus, knowledge of the mechanisms regulating the cell surface 
abundance of KCC3, such as the tyrosine phosphorylation described here, may be 
important for patient stratification or therapeutic options in certain tumor subtypes.
In conclusion, we found that the ion cotransporters NKCC2 and KCC3 are 
phosphorylated on an N-terminal tyrosine residue by protein kinase SYK and that 
experimental manipulation either of SYK expression levels or of its catalytic activity 
affect the cell surface abundance of these cotransporters. Interestingly, the very same 
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phosphorylation pathway leads to a decrease in NKCC2 but to an increase in KCC3 
surface levels. 
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Legends to Tables and Figures 
Table 1. List of 20 human ion channels or cotransporters involved in sodium, potassium 
or chloride transport that were inspected for the presence of the peptide motif Y-E/D-
E/D-X recognized and phosphorylated by SYK. 
Fig. 1. Protein kinase SYK phosphorylates NKCC2 and KCC3 in vitro. 
(A) The N-terminal domains of NKCC2 (amino acids 12-162) and KCC3 (amino acids 
2-135), as well as their phosphorylation site mutants containing phenylalanine instead 
of the predicted target tyrosine, were affinity-purified from lysed E. coli. Shown are 
Coomassie-stained polyacrylamide gels after electrophoretic separation of proteins 
from the indicated fractions: P- insoluble pellet after lysis; S- soluble lysate fraction, 
subsequent eluates E1-E3 from the Ni-NTA affinity column; M- molecular weight 
marker of 25 kDa.
(B) Wild-type (wt) SYK or its kinase-dead (kd) mutant were immunoprecipitated from 
transfected HEK293 cells and incubated in protein kinase buffer in the presence of 
radioactive ATP with the indicated recombinant substrate proteins (NBD1, NKCC2, 
NKCC2-Y45F, KCC3, KCC3-Y63F). Proteins were separated by SDS-PAGE and 
transferred to PVDF membrane. Top panel shows the radioactive proteins detected by 
exposing the membrane to x-ray films (Kinase Assay) and bottom panel the 
corresponding immunodetection (WB) to document the amounts of the indicated 
recombinant or immunoprecipitated proteins in the assay. Note that SYK-wt (but not 
SYK-kd) phosphorylated itself as well as NKCC2 and KCC3, whereas the mutants 
NKCC2-Y45F and KCC3-Y63F were poor substrates. NBD1 served as a previously 
described control (Mendes et al. 2011). As a negative control for the 
immunoprecipitation, lysates from cells transfected with an empty yellow-fluorescence 
protein vector (YFP-EV) were used.
Fig. 2. Experimental manipulation of either SYK expression levels or its catalytic activity 
modulates the levels of NKCC2 at the plasma membrane of HEK293 cells. 
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(A) Effect of overexpression of SYK mutants. Cells were co-transfected with Myc-
tagged NKCC2 and one of the following expression vectors: empty vector (EV), kinase-
dead YFP-tagged mutant SYK-kd, or constitutively active Flag-tagged mutant SYK-
Y352D. Data represent means ± SEM. Statistical analysis with ANOVA (p<0.02) 
followed by Tukey’s test (* = p < 0.05).
(B) Effect of depleting endogenous SYK expression. Cells were co-transfected with 
Myc-tagged NKCC2 and either a control (siLUC) or a SYK-specific (siSYK) siRNA. 
Note the successful downregulation of SYK expression. Data represent means ± SEM; 
* = p < 0.01 by T-test.
(C) Effect of inhibition of SYK catalytic activity. Cells were transfected with Myc-tagged 
NKCC2 and 24 h later treated for 1 h with control solvent DMSO, or with SYK inhibitors 
BAY 61-3606 or PRT062607. Data represent means ± SEM. Statistical analysis with 
ANOVA (p<0.001) followed by Tukey’s test (* = p < 0.05).
(A-C) After the treatments described above, cell surface proteins were biotinylated, 
cells then lysed and proteins resolved by SDS-PAGE and Western blot. Left panel: 
Detection of the indicated proteins in whole cell lysates (WCL) or in the biotinylated 
protein fraction (surface). The proliferating cell nuclear antigen protein (PCNA) served 
as a loading and contamination control, respectively. Lysates from cells incubated 
without the biotinylation reagent (w/o biotin) served as additional negative control. 
Right panel: corresponding quantification of NKCC2 detection in the biotinylated cell 
surface fraction, obtained from at least three independent experiments.
Fig. 3. Experimental manipulation of either SYK expression levels or its catalytic activity 
modulates the levels of KCC3 at the plasma membrane of HEK293 cells. Cells were 
transfected with Myc-tagged KCC3 and then treated and analyzed as described in the 
legend to Fig. 2. (A) Effect of overexpression of SYK mutants. Statistical analysis with 
ANOVA (p<0.002) followed by Tukey’s test (* = p < 0.05). (B) Effect of depleting 
endogenous SYK expression; * = p < 0.05 by T-test. (C) Effect of inhibition of SYK 
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catalytic activity. Statistical analysis with ANOVA (p<0.005) followed by Tukey’s test (* 
= p < 0.01).
Fig.4. SYK activity contributes to cell volume regulation.
(A) Inhibition of endogenous SYK activity modulates the cell surface expression of 
NKCC2 and KCC3 in opposite ways in the same cell. HEK293 cells were co-
transfected with Myc-tagged KCC3 and NKCC2, then treated and analyzed as 
described in the legend to Fig. 2. Note that NKCC2 or KCC3 were distinguished in 
whole cell lysates (WCL) or in the biotinylated protein fraction (surface) by using 
specific primary antibodies. Lower panel: corresponding quantification of NKCC2 and 
KCC3 detection in the biotinylated cell surface fraction, obtained from at least five 
independent experiments. Statistical analysis with ANOVA (p<0.01 for NKCC2, and 
p<0.001 for KCC3 data) followed by Tukey’s test (* = p < 0.05; ** = p < 0.01).
(B) Inhibition of endogenous SYK activity contributes to cell-volume regulation. 
HEK293 cells were co-transfected with Myc-tagged KCC3 and NKCC2, then treated 
for 1 h with control solvent DMSO, or with SYK inhibitor BAY 61-3606. Phase contrast 
microscopy images (600 x) were digitally recorded in isotonic medium, then cells were 
transferred to hypertonic for 10 min and the same cells imaged again. The area 
covered by cells was measured in the digitally recorded images, and differences 
obtained from three independent experiments were graphically displayed (lower 
panel). Data represent means ± SEM; * = p < 0.05 by T-test.
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Fig. S1. Expression of endogenous SYK, NKCC2 and KCC3 proteins in 
physiologically relevant cells types. (A) Mouse macula densa-derived cells 
(MMDD1) or (B) human proximal tubule HK-2 cells were grown on collagen-coated 
filter inserts (as described under Materials and methods), then cell surface proteins 
were biotinylated, cells lysed and proteins resolved by SDS-PAGE and Western blot 
for the detection of the indicated proteins in whole cell lysates (WCL) or in the 
biotinylated protein fraction (surface). The PCNA protein served as a loading and 
contamination control, respectively. (C) Detection of endogenous SYK protein 
expression in whole cell lysates of mouse MMDD1 and human HK-2 cells. Note that 
antibody affinity may not be comparable due to the species difference of both lysates. 
 
 
Transporter name gene SYK motif
NKCC2 SLC12A1 Y45EET
NKCC1 SLC12A2
NCC SLC12A3
KCC1 SLC12A4
KCC2 SLC12A5
KCC3 SLC12A6 Y63EEG
KCC4 SLC12A7
Cl-/HCO3-exchanger SLC26A3
Pendrin SLC26A4
Pendrin L1 SLC26A6
Sulfate Anion Transporter SLC26A7
Cl-/HCO3-exchanger SLC26A9,
ROMK KCNJ1
ENaC- alpha subunit SCNN1A
ENaC- beta subunit SCNN1B
ENaC- gamma subunit SCNN1G
ENaC- delta subunit SCNN1D
TRPV4 TRPV4
TRPV5 TRPV5
TRPV6 TRPV6
CFTR CFTR Y512DEY
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